Today at @UnionConference we unveiled data from our operational research: ⚙️@WHO recommended algorithms, for diagnosing tuberculosis in children can nearly double the number of children who can be initiated on lifesaving treatment. 🎉 https://t.co/pWa4jaGdAy

This World AMR Awareness Week, join a discussion on antimicrobial resistance in conflict-affected settings, where AMR's impact is severe due to limited access to infection prevention, diagnostics, and antimicrobials. 📅 Thur 20 Nov 🕐 13:00 – 15:30 CET 🔗

Ensuring people have access to insulin and diabetes care is essential, especially during emergencies and in humanitarian settings where diabetes care is even more limited. Learn more ⬇️ https://t.co/fApFxXI3dI

Today is World Diabetes Day. More than 800 million people have diabetes, most of whom live in low- and middle-income countries. For people w/ type 1 diabetes, insulin is lifesaving, but it's often unavailable in low-resource and emergency settings and unaffordable elsewhere.

Scientists discovered insulin over 100 years ago, envisioning a world where everyone could access #diabetes treatment. But it is often unavailable or unaffordable. Ahead of World Diabetes Day tomorrow, we’re calling for affordable & available insulin pens for all.

It's starting soon! https://t.co/Dt4OteiCmz

Today @who released their 2025 #tuberculosis report, and figures remain unacceptable: 1.2 million children and young adolescents fell ill in 2024, and 43% were never diagnosed and thus missed lifesaving treatment. Act now to close the deadly gap! https://t.co/uUNhgizV1p

https://t.co/Mw7tfzMrfr

Half of children and young adolescents with tuberculosis are not diagnosed and therefore do not receive lifesaving treatment… but why? Take a look at the causes of this deadly gap, which we’ll be discussing in next week’s panel discussion. https://t.co/ggf8XyeLdf

Every child withTB deserves a healthy childhood. Yet in 2023, 1.25M fell ill with TB and nearly half were never diagnosed, thus never treated. Join our webinar moderated by @johngreen where survivors and treatment providers will discuss how to close these deadly gaps.

"Antibiogo was developed in collaboration with the people and countries that need it." We spoke on Antibiogo last week at the World Health Summit, sharing how it was developed by, for, and with the countries where we work. https://t.co/dQwkFICsPN #Innovation #WHS2025

🦠 It's estimated that by 2050, antibiotic resistance will cause 8.22 million deaths per year. To try and combat this, MSF launched Antibiogo, a free diagnostic aid app to combat antibiotic resistance by improving access to patient diagnoses. Learn more:

➡️ @Saludporderecho reports that in Spain the public price of WHO recommended six-month treatment BPaLM regimen is priced at €58,000. In contrast, LMICs can access the same regimen for less than €250. https://t.co/AMJgpKx1dk

💊Patents, trade policy, and why people's access to the medicines they need is at stake. @johnroshanj on India’s Free Trade Agreements with high-income countries, how they could mean higher medicine prices around the world, and why transparency in their negotiation matters.

When Johnson & Johnson tried to extend its patent monopoly on a lifesaving TB drug @MSF's Candice Andisiwe Sehoma sent TB survivor Phumeza Tisile to India to challenge it. It resulted in a 40% price drop for SA.

In the past 3 years, Poland has taken steps to improve TB treatment access by aligning national policies with WHO recommendations. But, many EU & EEA countries have not updated their guidelines and continue to grapple with barriers in accessing effective medicines and treatment.

Olga*, a person living with DR-TB in Warsaw, was started on the all-oral, six-month DR-TB regimen as recommended by the WHO to replace the previous DR-TB treatment regimen which was less effective and more toxic.

MSF first witnessed the systemic gaps in access to WHO-recommended #tuberculosis treatments in 2022 when we launched a response in Poland to assist Ukrainian refugees and other migrants in accessing tuberculosis treatment. A TB survivor shared her experience 🧵

At a panel discussion yesterday in Brussels, we urged policymakers, parliamentarians, regulatory agencies, and procurement bodies in the EU and the EEA to take urgent steps to bridge the gap in accessing tuberculosis treatment in the region. https://t.co/mRYOa47UAO

⏰ Tomorrow! Don’t miss our panel on improving access to TB medicines in EU/EEA. People with TB still face barriers to effective treatment & prevention, let's discuss solutions. Register Now👉 https://t.co/adSFpIsbMB